David J. Truscello, J. John, B. Blair, Yaser Khalid, N. Dasu
{"title":"S45 Highlighting Disparities and Outcomes in Pregnant Patients With Inflammatory Bowel Disease (IBD): Does Race Matter?","authors":"David J. Truscello, J. John, B. Blair, Yaser Khalid, N. Dasu","doi":"10.14309/01.ajg.0000995920.77325.15","DOIUrl":null,"url":null,"abstract":", immunohistochemical staining for IgG4 was performed on the patient ’ s colon biopsies, which revealed a high percentage of the IgG cells in the lamina propria with . 50% positivity for IgG4. This con fi rmed the patient ’ s IgG4 mediated colitis, and he has now started rituximab therapy. Conclusions: We demonstrate a case of IgG4-RD misclassi fi ed as CD and GPA and emphasize the importance of consideration of this rare disorder in appropriate patients. Clinical follow-up and response to rituximab will be described at the time of this case presentation.","PeriodicalId":188050,"journal":{"name":"The American Journal of Gastroenterology","volume":"239 ","pages":"S12 - S13"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14309/01.ajg.0000995920.77325.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
, immunohistochemical staining for IgG4 was performed on the patient ’ s colon biopsies, which revealed a high percentage of the IgG cells in the lamina propria with . 50% positivity for IgG4. This con fi rmed the patient ’ s IgG4 mediated colitis, and he has now started rituximab therapy. Conclusions: We demonstrate a case of IgG4-RD misclassi fi ed as CD and GPA and emphasize the importance of consideration of this rare disorder in appropriate patients. Clinical follow-up and response to rituximab will be described at the time of this case presentation.